As mutations in BRCA1 and BRCA2 may predict response to PARP inhibition regardless of cancer type, clinical trials testing the efficacy of PARP inhibitors in cancer with BRCA1 or BRCA2 mutations may need to be extended to all disease types, including HCC. This evidence concerns the gene PARP1 and hepatocellular carcinoma.